Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
spinal muscular atrophy
9
×
boston blog main
national blog main
national top stories
new york top stories
biotech
boston top stories
gene therapy
new york blog main
novartis
san francisco top stories
fda
national
san diego blog main
san diego top stories
san francisco blog main
biogen
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
zolgensma
deals
medicare
startups
eli lilly
johnson & johnson
medicaid
What
bio
roundup
drug
alzheimer’s
gene
therapy
biotech
democrats
healthcare
investment
ipo
long
medicine
new
prices
public
remains
week
years
age
allogene
america
annual
approved
assessed
atrophy
attention
bigger
biggest
biogen
cancer
come
communities
companies
conference
congress
continues
convoluted
crispr
crude
Language
unset
Current search:
" spinal muscular atrophy "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More